argenx stock: VYVGART sales rise 54% in third quarter

argenx reported strong third-quarter 2026 results on October 22, with VYVGART continuing to drive commercial growth and the immunology company advancing several pipeline programs. The company said global product net sales reached 1.7 billion US dollars, while management highlighted further expansion opportunities in neurology and rheumatology. The results and business update were published by GlobeNewswire on behalf of argenx.

Product net sales rose 54 percent year over year to 1.721 billion US dollars in the three months ended September 30, 2026, up from 1.127 billion US dollars a year earlier. Sales also increased 13 percent from the second quarter. For the first nine months, product net sales reached 4.534 billion US dollars, compared with 2.866 billion US dollars in the same period of 2025.

Profit growth follows commercial momentum

Total operating income rose to 1.751 billion US dollars in the quarter from 1.151 billion US dollars a year earlier. Operating profit increased to 486 million US dollars from 346 million US dollars, while profit for the period climbed to 506 million US dollars from 344 million US dollars. Basic profit per share rose to 8.07 US dollars from 5.61 US dollars.

Expenses also expanded as argenx invested in research, development and commercialization. Research and development expenses reached 503 million US dollars, compared with 359 million US dollars in the prior-year quarter. Selling, general and administrative expenses rose to 598 million US dollars from 336 million US dollars and included approximately 150 million US dollars in acquisition-related costs linked to the Forte Biosciences transaction.

Cash, cash equivalents and current financial assets totaled 3.7 billion US dollars at September 30, 2026, after argenx paid approximately 2.1 billion US dollars for Forte, net of acquired cash. The company expects combined research and development and selling, general and administrative expenses of approximately 4 billion US dollars for the full year 2026, including the Forte transaction-related costs.

Pipeline milestones set the next catalysts

argenx submitted a supplemental biologics license application for VYVGART in ocular myasthenia gravis and said the pediatric generalized myasthenia gravis application had been accepted for priority review. The pediatric program carries a target FDA action date in February 2027. An autoinjector for VYVGART Hytrulo is expected to launch in the second half of 2027 for approved indications.

Positive Phase 3 ALKIVIA results supported the company's plans for VYVGART in immune-mediated necrotizing myopathy. argenx said the related filing remains on track for submission by the end of 2026, while an additional registrational study is planned in dermatomyositis. Topline results from the Phase 3 EMPASSION study of empasiprubart in multifocal motor neuropathy are expected in December 2026.

Beyond VYVGART and empasiprubart, argenx is advancing FB102 into Phase 3 development in celiac disease after positive Phase 2 results. The company also expects to begin a Phase 3 study of adimanebart in congenital myasthenic syndromes in 2026 and continues Phase 2 work on ARGX-121 in IgA nephropathy. Management said the broader pipeline supports its ambition to reach 50,000 patients, secure 10 labeled indications and move five pipeline candidates into registrational development by 2030.

argenx stock traded at 803.60 euros on Lang & Schwarz at 10:35 CET on Friday, October 30, 2026. Investors can follow the real-time quote of argenx stock.

European equities remain the broader market backdrop for Dutch-listed companies; see the latest AEX market coverage.

Further company-specific developments are available in more news and analyses on argenx stock.